Ovid Trifan

487 total citations
6 papers, 83 citations indexed

About

Ovid Trifan is a scholar working on Oncology, Immunology and Neurology. According to data from OpenAlex, Ovid Trifan has authored 6 papers receiving a total of 83 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Immunology and 2 papers in Neurology. Recurrent topics in Ovid Trifan's work include Cancer Immunotherapy and Biomarkers (4 papers), Immunotherapy and Immune Responses (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Ovid Trifan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Immunotherapy and Immune Responses (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Ovid Trifan collaborates with scholars based in United States. Ovid Trifan's co-authors include Osama E. Rahma, Christopher R. Cabanski, Gauri R. Varadhachary, Vanessa M. Hubbard-Lucey, Andrew H. Ko, Theresa LaVallee, Mark H. O’Hara, Eileen M. O’Reilly, Zev A. Wainberg and Jaclyn P. Lyman and has published in prestigious journals such as Cancer Research, Neuro-Oncology and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Ovid Trifan

6 papers receiving 83 citations

Peers

Ovid Trifan

ONCOL

IMMUN

PRM

CR

MB

Takamasa Ishino Japan

Carly Reeder United States

Eline de Boer Norway

G. Lefebvre France

Shusuke Kawashima Japan

Eva Sum Germany

Jaya Thomas United Kingdom

Jill McKay-Fleisch United States

Jaklin Gukasyan United States

Takamasa Ishino Japan

Ovid Trifan

72 ×0.9

ONCOL

69 ×1.3

IMMUN

19 ×1.7

PRM

10 ×1.0

CR

26 ×4.3

MB

Citations per year, relative to Ovid Trifan Ovid Trifan (= 1×) peers Takamasa Ishino

Countries citing papers authored by Ovid Trifan

Since Specialization

Citations

This map shows the geographic impact of Ovid Trifan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ovid Trifan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ovid Trifan more than expected).

Fields of papers citing papers by Ovid Trifan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ovid Trifan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ovid Trifan. The network helps show where Ovid Trifan may publish in the future.

Co-authorship network of co-authors of Ovid Trifan

This figure shows the co-authorship network connecting the top 25 collaborators of Ovid Trifan. A scholar is included among the top collaborators of Ovid Trifan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ovid Trifan. Ovid Trifan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Lindsay, Holly, Arzu Onar‐Thomas, Mehmet Koçak, et al.. (2020). EPCT-02. PBTC-051: FIRST IN PEDIATRICS PHASE 1 STUDY OF CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M IN PEDIATRIC SUBJECTS WITH RECURRENT/REFRACTORY BRAIN TUMORS. Neuro-Oncology. 22(Supplement_3). iii304–iii304. 2 indexed citations

2.

O’Hara, Mark H., Eileen M. O’Reilly, Rosemarie Mick, et al.. (2019). Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Clinical Trials. CT004–CT004. 13 indexed citations

3.

O’Hara, Mark H., Eileen M. O’Reilly, Rosemarie Mick, et al.. (2019). Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Cancer Research. 79(13_Supplement). CT004–CT004. 55 indexed citations

4.

Kluger, Harriet M., Sarah A. Weiss, Anthony J. Olszanski, et al.. (2019). Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Clinical Trials. CT089–CT089. 2 indexed citations

5.

Kluger, Harriet M., Sarah A. Weiss, Anthony J. Olszanski, et al.. (2019). Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Cancer Research. 79(13_Supplement). CT089–CT089. 10 indexed citations

6.

Björck, Pia, et al.. (2015). The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P198–P198. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact